Life Science News

Groundbreaking psychedelic study will investigate binge eating disorder, compulsive sexual behavior, and internet gaming disorder

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn), a biotechnology company developing and delivering psychedelic medicines to better treat addiction, announced today that it has received ethical committee approval to expand its existing ketamine study beyond Gambling Disorder to include three other behavioral addictions including Binge Eating Disorder, Compulsive Sexual Behaviour and Internet Gaming Disorder.

The basket study, which will be another world's first, is led by Prof. Celia Morgan, Awakn's Head of Ketamine-Assisted Therapy for Addiction, Professor of Psychopharmacology at the University of Exeter, U.K., and an internationally respected expert in the therapeutic use of ketamine. Professor Morgan's work will investigate a new treatment approach for these behavioral addictions, trying to harness a window in which the brain is able to make new connections. The study will explore and monitor whether the ketamine can increase neuroplasticity using EEG (Electroencephalogram).

Professor Morgan commented, "We are delighted to expand this research and to make further inroads into a treatment area that has had no material pharmacological advancements in far too long, all the while the number of people suffering has steadily increased. We hope this will give us valuable insights to push our ketamine program forward and help these people as quickly as possible."

There are currently no licensed pharmacological treatments for behavioral addictions or disorders available, and the need to find new and effective treatment options has never been more important. Behavioural addictions have devastating consequences for individuals and their families, affecting physical and mental health, and increasing mortality from suicide. The global populations affected by behavioural addictions are massive with Binge Eating Disorder affecting up to 110 million people; Internet Gaming Disorder affecting 238 million; Sexual Compulsive Behaviour affecting up to 350 million; and Gambling Disorder up to 450 million people.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic medicine to better treat addiction. Awakn's team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will also deliver evidence backed psychedelic therapies for addiction in clinics in the UK and Europe and through licencing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Notice Regarding Forward Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including the intended business of the Company, the expansion of the Company's business, generation of revenue. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's and Awakn's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109023

News Provided by Newsfile via QuoteMedia

AWKN:AQL
Awakn Life Sciences Corp.

Awakn Life Sciences Corp.


Keep reading...Show less
Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer

Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer

Dr. Dhandayudham Brings Significant Frontline Addiction and Mental Health Medical Leadership Experience to Awakn

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today that Dr. Arun Dhandayudham is joining Awakn as its Chief Medical Officer. Dr. Ben Sessa is stepping back from his role as CMO to become Awakn's Head of Psychedelic Medicine, allowing him to continue his work in research, academic and training activities, as well as a greater focus on the day-to-day treatment of his clients as the Lead Physiatrist for Awakn Clinics Bristol.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Awakn Life Sciences to Participate in Upcoming May 2022 Conferences

Awakn Life Sciences to Participate in Upcoming May 2022 Conferences

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, announced today that Awakn's management team is scheduled to present at the following upcoming May 2022 conferences.

PSYCH Symposium: London 2022

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing

KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27 th and 28 th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

REGISTER OR LOGIN NOW AT: https://bit.ly/3OGHgD4

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results

Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, today is reporting its financial results and business highlights for the three and twelve months ended January 31, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

Anthony Tennyson, Chief Executive Officer of Awakn Life Sciences, stated, "Awakn's fiscal year 2021 was a foundational year for the Company. We established our business model of researching, developing, and delivering combined therapeutics to treat addiction, with a near term focus on Alcohol Use Disorder (AUD) a condition affecting 400m people globally. This business model enables us to develop new and potentially more effective combined therapeutics for treating addiction and also to gather real world data to support interactions with regulatory agencies prior to commercializing our combined therapeutics at scale."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering revolutionary therapeutics to treat addiction, today is providing shareholders with a business update on its three fully-operational ketamine-assisted therapy clinics, two in the UK and one in Norway.

Awakn's clinics team consists of some of the world's leading authorities in the ketamine/psychedelic-assisted therapy industry, including Dr. Ben Sessa, Awakn's Chief Medical Officer; Dr. Laurie Higbed, Awakn's Lead Psychologist, Prof. Celia Morgan, Awakn's Head of Ketamine-Assisted Therapy, Dr. Lowan Stewart, Managing Director - Nordics and James Collins, Managing Director, Awakn Clinics and Chief Operating Officer of Awakn.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Optimi Health

Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has completed the acquisition of a diverse catalog of psilocybin and functional mushroom strains intended for cultivation in its 20,000 square foot, EU-GMP compliant facility in Princeton, British Columbia.

The Company's acquisition includes 24 psychedelic and nine functional strains, giving it one of the largest genetic banks in the sector. Formulated psychedelic strains will be made available to licensed researchers, Canada's Special Access Program (SAP), as well as being utilized for on-site research in Optimi's recently expanded analytical laboratory, while the functional strains will be optimized for the Company's growing whole body, natural supplement brand, Optimi Life .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nirvana Signs Letter of Intent with Innovate Phytotechnologies Inc.

Nirvana Signs Letter of Intent with Innovate Phytotechnologies Inc.

Collaboration with British Columbia Lab to open doors for psychedelics product development and distribution.

Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products, is pleased to announce that it has signed a letter of intent with Innovate Phytotechnologies Inc. (INVP) for the development and distribution of the Company's psilocybin and psilocin based products. The strategic relationship will begin with the production of 20g each of psilocybin and psilocin and will increase with market demands.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2022 Jefferies Global Healthcare Conference, June 8-10, 2022 .

(PRNewsfoto/Seelos Therapeutics, Inc.)

Raj Mehra, Ph.D., Chairman and CEO and Michael Golembiewski , CFO, will present on Friday, June 10th at 12:00 PM ET and host 1x1 meetings.

The 2022 Jefferies Global Healthcare Conference is an annual gathering where over 500 public & private healthcare companies and 3,000 leading executives, institutional investors, private equity investors & VCs will address near-term and long-term investment opportunities and discuss the current trends driving healthcare in the U.S. and internationally.

Presentation webcast registration may be accessed here .

For questions about the conference, please email healthcareconference@jefferies.com .

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com , the content of which is not incorporated herein by reference.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-2022-jefferies-global-healthcare-conference-301545553.html

SOURCE Seelos Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways to participate in upcoming Citi's Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows:

  • Citi's Biopharma Virtual Co-Panel Day: panel "Mood Disorders/Mental Health Panel" at 11:00 am ET on 18 May 2022
  • HC Wainwright Global Investments Conference: presentation at 9:00 am ET on 24 May 2022

A live audio webcast of both events will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following each event. For more information, please visit ir.compasspathways.com.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health

Optimi Health Completes Expansion Of On-Site Analytical Laboratory

Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility.

The on-site lab is purpose built inside one of Optimi's EU-GMP capable 10,000 square foot, state-of-the-art indoor growing facilities dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms. Optimi Chief Science Officer, Justin Kirkland, will oversee the Company's analytical operations.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

-

Highlights:
  • End of phase II meeting held with FDA
  • Award of Innovation Passport as part of the UK MHRA Innovative Licensing and Access Pathway ILAP
  • Finalising phase III in TRD program design to be ready for second half of 2022
  • Pioneering collaboration with King's College London and South London and Maudsley NHS Foundation Trust, to create The Centre for Mental Health Research and Innovation in the UK
  • Cash position at 31 March 2022 of $243.7 million
  • Conference call today at 8:00am ET (1:00pm UK)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2022 and gave an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×